SCHEMBL2397495

SCHEMBL2397495

COc1cccc(C(C)C(=O)Cl)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
NFE2L2 Q16236 2/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
LPAR1 Q92633 1/20 0.41
ATM Q13315 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
KCNK3 O14649 1/20 0.40
KCNK9 Q9NPC2 1/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
USP2 O75604 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27602953 0.86 KMT2A (0.49) KMT2ACA12CA1CA2CA7
SCHEMBL490689 0.85 PTGS1 (0.54) KMT2AMEN1NFE2L2CA12CA1
SCHEMBL5742063 0.85 AOC3 (0.45) CA1CA2CA7CA9MAPT
SCHEMBL490336 0.80 MAPT (0.44) KMT2AMEN1NFE2L2ALDH1A1MAPT
SCHEMBL15750738 0.77 SMN1; SMN2 (0.44) KMT2AMEN1NFE2L2CA12CA1
SCHEMBL670715 0.77 MEN1 (0.49) KMT2AMEN1NFE2L2ATMALDH1A1
SCHEMBL683593 0.76 NFE2L2 (0.47) KMT2AMEN1NFE2L2CA12CA1
SCHEMBL17894142 0.76 NFE2L2 (0.46) KMT2AMEN1NFE2L2CA12CA1
Hydrochloric Acid SCHEMBL5820053 0.75 MEN1 (0.48) KMT2AMEN1NFE2L2ATMALDH1A1
SCHEMBL4697541 0.75 FABP4 (0.48) KMT2AMEN1NFE2L2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
EP-2542549-A2 INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2013-01-09 EP disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
WO-2011107530-A2 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224259-A1 NOVEL INHIBITORS QPCT, GLUL, GLS KMT2A 1909/4885MEN1 2453/4885NFE2L2 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.